Format

Send to

Choose Destination
Nat Rev Drug Discov. 2002 Nov;1(11):911-6.

Hepatitis C virus replicons: potential role for drug development.

Author information

1
Department of Molecular Virology, Institute of Hygiene, University of Heidelberg, Otto-Meyerhof-Zentrum, Im Neuenheimer Feld 350, 69120 Heidelberg, Germany. ralf_bartenschlager@med.uni-heidelberg.de

Abstract

The development of causal therapies depends on the availability of systems to determine the inhibitory capacity of a compound. As viruses are obligate intracellular parasites, the efficacy of an antiviral drug is usually evaluated in a cell-culture system. Unfortunately, the hepatitis C virus, the principal causative agent of acute and chronic liver disease, cannot be propagated efficiently in the laboratory. However, the recent development of a replicon system opens up an encouraging possibility for drug discovery.

PMID:
12415250
DOI:
10.1038/nrd942
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center